Diabetes 54:1023-1031, 2005
© 2005 by the American Diabetes Association, Inc.
Adipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity
Erin E. Kershaw1,
Nicholas M. Morton2,
Harveen Dhillon1,
Lynne Ramage2,
Jonathan R. Seckl2, and
Jeffrey S. Flier1
1 Division of Endocrinology and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
2 Endocrinology Unit, Molecular Medicine Center, University of Edinburgh, Western General Hospital, Edinburgh, U.K
Local glucocorticoid (GC) action depends on intracellular GC metabolism by 11ß-hydroxysteroid dehydrogenases (11ßHSDs). 11ßHSD1 activates GCs, while 11ßHSD2 inactivates GCs. Adipocyte-specific amplification of GCs through transgenic overexpression of 11ßHSD1 produces visceral obesity and the metabolic syndrome in mice. To determine whether adipocyte-specific inactivation of GCs protects against this phenotype, we created a transgenic model in which human 11ßHSD2 is expressed under the control of the murine adipocyte fatty acid binding protein (aP2) promoter (aP2-h11ßHSD2). Transgenic mice have increased 11ßHSD2 expression and activity exclusively in adipose tissue, with the highest levels in subcutaneous adipose tissue, while systemic indexes of GC exposure are unchanged. Transgenic mice resist weight gain on high-fat diet due to reduced fat mass accumulation. This improved energy balance is associated with decreased food intake, increased energy expenditure, and improved glucose tolerance and insulin sensitivity. Adipose tissue gene expression in transgenic mice is characterized by decreased expression of leptin and resistin and increased expression of adiponectin, peroxisome proliferatoractivated receptor , and uncoupling protein 2. These data suggest that reduction of active GCs exclusively in adipose tissue is an important determinant of a favorable metabolic phenotype with respect to energy homeostasis and the metabolic syndrome.
Address correspondence and reprint requests to Erin E. Kershaw, MD, Division of Endocrinology and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. E-mail: ekershaw{at}bidmc.harvard.edu

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Boullu-Ciocca, V. Achard, V. Tassistro, A. Dutour, and M. Grino
Postnatal Programming of Glucocorticoid Metabolism in Rats Modulates High-Fat Diet-Induced Regulation of Visceral Adipose Tissue Glucocorticoid Exposure and Sensitivity and Adiponectin and Proinflammatory Adipokines Gene Expression in Adulthood
Diabetes,
March 1, 2008;
57(3):
669 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. K. Tamashiro, M. M. N. Nguyen, M. M. Ostrander, S. R. Gardner, L. Y. Ma, S. C. Woods, and R. R. Sakai
Social stress and recovery: implications for body weight and body composition
Am J Physiol Regulatory Integrative Comp Physiol,
November 1, 2007;
293(5):
R1864 - R1874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Caprio, B. Feve, A. Claes, S. Viengchareun, M. Lombes, and M.-C. Zennaro
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis
FASEB J,
July 1, 2007;
21(9):
2185 - 2194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kim, K. A. Temple, S. A. Jones, K. N. Meredith, J. L. Basko, and M. J. Brady
Differential Modulation of 3T3-L1 Adipogenesis Mediated by 11beta-Hydroxysteroid Dehydrogenase-1 Levels
J. Biol. Chem.,
April 13, 2007;
282(15):
11038 - 11046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, et al.
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab,
April 1, 2007;
292(4):
E1213 - E1222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Tomlinson, M. Sherlock, B. Hughes, S. V. Hughes, F. Kilvington, W. Bartlett, R. Courtney, P. Rejto, W. Carley, and P. M. Stewart
Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis
J. Clin. Endocrinol. Metab.,
March 1, 2007;
92(3):
857 - 864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Qi and B. Rodrigues
Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism
Am J Physiol Endocrinol Metab,
March 1, 2007;
292(3):
E654 - E667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. McMaster and D. W. Ray
Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects
Exp Physiol,
March 1, 2007;
92(2):
299 - 309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. Densmore, N. M. Morton, J. J. Mullins, and J. R. Seckl
11{beta}-Hydroxysteroid Dehydrogenase Type 1 Induction in the Arcuate Nucleus by High-Fat Feeding: A Novel Constraint to Hyperphagia?
Endocrinology,
September 1, 2006;
147(9):
4486 - 4495.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Paulsen, S. B. Pedersen, J. O. L. Jorgensen, S. Fisker, J. S. Christiansen, A. Flyvbjerg, and B. Richelsen
Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
1093 - 1098.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Diabetes Association.
|
|
| |
|